Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Eton Pharmaceuticals (NASDAQ:ETON) released its earnings results on Thursday. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19, FiscalAI reports. The company had revenue of $57.93 million for the quarter, compared to analysts’ expectations of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 144.74%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Eton reported record third-quarter revenue of $57.9 million, up 158% year over year, with growth from HEMANGEOL and strength across its portfolio. The company raised 2026 revenue guidance to more than $175 million.
• Profitability and cash generation improved sharply: adjusted gross margin was 80%, adjusted EBITDA was $28.5 million (49% of revenue), and cash from operations was $35 million. Eton ended the quarter with $55.6 million in cash after a $5 million debt prepayment, and now expects a full-year adjusted EBITDA margin above 40%.
• LIBERVANT adds a potential near-term growth driver in seizure-cluster treatment; Eton expects to launch in April 2027, subject to FDA approval and resolution of exclusivity restrictions. Management sees opportunity for its portable buccal film in a U.S. market it estimates exceeds $450 million annually.
• Management sees significant pipeline upside, particularly from ASN-001, a topical hemangioma treatment it believes could serve a broader population than HEMANGEOL; a short bioavailability study is underway, with an NDA submission targeted for mid-2027 and a potential 2028 launch. Other programs include a planned 2027 study of ET-900 for infantile spasms and a potential 2027 launch for glibenclamide oral suspension.
• ET-700’s proof-of-concept study found treatment-related adverse events in 1 of 12 participants versus 8 of 12 on GALZIN, but it blocked copper absorption less effectively than GALZIN. Eton attributed the efficacy gap to a release profile it says was too slow and plans to test faster-release formulations in 2027, leaving the program’s next steps dependent on further results.

Eton Pharmaceuticals Price Performance

Shares of ETON stock traded up $9.31 during mid-day trading on Friday, hitting $56.46. The company had a trading volume of 1,269,987 shares, compared to its average volume of 415,837. Eton Pharmaceuticals has a 52-week low of $14.27 and a 52-week high of $66.37. The stock’s 50 day moving average price is $54.80 and its 200-day moving average price is $36.46. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The company has a market capitalization of $1.61 billion, a P/E ratio of 37.39 and a beta of 0.89.

Key Stories Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

Insiders Place Their Bets

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the sale, the director directly owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Krempa sold 25,000 shares of Eton Pharmaceuticals stock in a transaction on Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the sale, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 79,166 shares of company stock valued at $4,809,672. 16.49% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Zacks Research upgraded Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. B. Riley Financial restated a “buy” rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Canaccord Genuity Group upped their price objective on Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings raised Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Finally, HC Wainwright increased their target price on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $77.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.